Loading...
XSTO
BICO
Market cap146mUSD
Dec 05, Last price  
19.88SEK
1D
1.38%
1Q
-16.47%
Jan 2017
-4.77%
IPO
42.00%
Name

BICO Group AB

Chart & Performance

D1W1MN
XSTO:BICO chart
P/E
P/S
0.71
EPS
Div Yield, %
Shrs. gr., 5y
17.99%
Rev. gr., 5y
112.11%
Revenues
1.95b
-13.09%
013,188,00045,337,000105,457,000176,793,0001,257,300,0002,239,500,0001,946,300,000
Net income
-6m
L-99.34%
0155,0001,183,000581,000-61,888,000-229,200,000-835,700,000-5,500,000
CFO
158m
P
-179,000-12,263,000-15,818,000-71,817,000-409,200,000-269,400,000158,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
IPO date
Nov 03, 2016
Employees
1,069
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122022‑122021‑122020‑082019‑082018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT